Liver tumor-infiltrating lymphocytes also express higher levels of lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin-3 (TIM-3), and T cell immunoglobulin and ITIM domain (TIGIT), providing support for exploring the next generation of checkpoints in liver cancer immunotherapy (4, 5). The gene discussed is LAG3; the disease is liver cancer.